QLT Inc.  

(Public, TSE:QLT)   Watch this stock  
Find more results for QLT
6.07
+0.12 (2.02%)
Aug 29 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.07 - 6.10
52 week 4.30 - 7.90
Open 6.10
Vol / Avg. 240.00/1,320.00
Mkt cap 309.98M
P/E     -
Div/yield 4.12
EPS -0.60
Shares 51.08M
Beta -0.01
Inst. own     -
Nov 5, 2014
Q3 2014 QLT Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 5, 2014
Q2 2014 QLT Inc. Earnings Release
Jun 26, 2014
Auxilium Pharmaceuticals Inc to Merge with QLT Call - Webcast
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -22.34% -9.14%
Return on average equity -23.29% -9.46%
Employees 37 -
CDP Score - -

Address

Suite 250, 887 Great Northern Way
VANCOUVER, BC V5T 4T5
Canada
+1-604-7077000 (Phone)
+1-604-7077001 (Fax)

Website links

Description

QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. It develops QLT091001, a synthetic retinoid compound for the potential treatment of certain inherited retinal degenerative diseases. In September 2012,it sold all of its assets related to Visudyne to Valeant Pharmaceuticals International, Inc. (Valeant). It also sold Qcellus laser and certain other photodynamic therapy intellectual property, In April 2013, it sold its punctal plug drug delivery system (PPDS) technology (Technology) to Mati Therapeutics Inc. (Mati). It is engaged in providing transition services to Valeant concerning most of the aspects of the Visudyne and Qcellus laser business. It is conducting Phase Ib clinical proof-of-concept studies of QLT091001, a synthetic retinoid replacement therapy for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, in patients with Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

Officers and directors

Jason M. Aryeh Independent Chairman of the Board
Age: 45
Sukhi Jagpal Chief Financial Officer
Age: 39
Geoffrey F. Cox Ph.D. Independent Director
Age: 70
John W. Kozarich Ph.D. Independent Director
Age: 64
Jeffrey A. Meckler Independent Director
Age: 47
Stephen L. Sabba M.D. Independent Director
Age: 54
John C. Thomas Jr. Independent Director
Age: 60